Main Tasks: 圍繞公司業務，積極開發與國家相關部門的項目合作，其合作主要目標對象：
國家衛生部，國家發改委，勞動和社會保障部，國家食品與藥品監督管理局等；
其合作伙伴也包括RDPAC與制藥界同仁等；
也包括公司內部的各相關部門，如糖尿病事業部，生物藥品部，人力資源部，醫學部等；
Developing government cooperation projects, based on businesses needs, with MOH, NDRC, MOLSS,SFDA. And work together with other business partners, such as RDPAC ,and internal departments, including DBD, BBU, HR, and Med etc., for successful government cooperations. 開發、運作及管理WDF在中國的實施項目，包括但不僅限于目前的與衛生部、西藏、青島、及凝血因子7項目；
其合作伙伴也包括公司內部的各相關部門，如糖尿病事業部，生物藥品部，人力資源部，醫學部等；
Develop and manage the operation of WDP projects in China. The projects include, but not limited, the MOH project, Tibet project, QingDao project and NovoSeven project. And Strengthen the cooperation between the related internal departments, such as DBD, BBU, HR and Med for the projects. 與WDF（世界糖尿病基金會）保持密切并良好有效的溝通；
Ensure good communication with WDF Qualifications: 大學本科以上學歷，醫藥相關專業為佳；
Bachelor’s degree or above, major in medical or related is preferred 具優秀的英文書寫與口頭表達能力；
Excellent English on both written and verbal. 良好的溝通能力與獨立處理問題能力；
Strong communication skill and ability to work independently 具備良好的項目開發與管理能力；
Good capability on project developing and management 強烈的責任感與服務意識；
with strong responsibility and service minded 并優先考慮以下條件：
Working experience on government affairs in multinational enterprise or experience in medical care related authority is highly preferred. 跨國企業政府事務工作經驗，或有醫療衛生行業政府工作經驗背景 ；

企業介紹:
About Novo Nordisk Novo Nordisk is one of the world's leading bio-pharmaceutical companies and the world leader in insulin production for diabetes treatment. With headquarters in Copenhagen, Denmark, Novo Nordisk employs approximately 21,000 people in more than 70 countries and markets its products in 179 countries. There are also production plants in occident. Novo Nordisk has a long history since 1923. For over 80 years, Novo Nordisk continues to adopt advanced biotechnology to improve the research and means of production for insulin. It is a major force in insulin manufacture and diabetes treatment. The company was the first to introduce longer acting insulin (NPH and Lente insulin), pre--mixed insulin, highly purified insulin (MC and RI insulin), human insulin and insulin pens, which tremendously improved the level of diabetes treatment and control, and life quality of people with diabetes. In addition, Novo Nordisk is in a leading position within the areas of coagulation disorders, growth disorders and hormone replacement therapy. As early as 1960s, Novo Nordisk's products have been introduced to the China market. In 1994, Novo Nordisk board decided to land a strategic investment project in China. Novo Nordisk (Tianjin) Biotechnology Co., Ltd. was then set up in China. The company's headquarters and Biotechnology R&D Center are located in Beijing while its production plant is in Tianjin. For more information, please visit: http://www.novonordisk.com.cn 諾和諾德公司概覽： 諾和諾德是世界領先的生物制藥公司，在用于糖尿病治療的胰島素開發和生產方面居世界領先地位。諾和諾德總部位于丹麥首都哥本哈根，員工總數21,000人，分布于70個國家，產品銷售遍布179個國家。在歐美均建有生產廠。 諾和諾德的歷史最早可追溯至1923年。近80年來，諾和諾德不斷運用先進的生物技術完善胰島素研究和生產手段，取得突破性進展，成為這一領域的先驅。諾和諾德率先推出長效胰島素，預混胰島素，高純胰島素，人體胰島素和胰島素注射筆。同時，諾和諾德又率先推出新一類的口服降糖藥-諾和龍，從而極大地提高了糖尿病治療和控制水平，改善了糖尿病人的生活質量。此外，諾和諾德還在凝血治療、生長保健以及激素替代療法等很多方面居世界領先地位。 諾和諾德的產品60年代初就已進入中國市場。1994年初，諾和諾德董事會通過了在中國實施戰略投資的計劃，在北京建立諾和諾德（中國）制藥有限公司總部和生物技術研究發展中心，并在天津興建現代化生產工廠。欲了解詳情，請訪問諾和諾德中國網站：http://www.novonordisk.com.cn